BRL 26830A

structure given in first source

Also Known As:

BRL 26830; BRL-26830A; methyl 4-(2-((2-hydroxy-2-phenethyl)amino)propyl)benzoate-2-butanedioate; Benzoic acid, 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)-, methyl ester, (R*,R*)-(+-)-, (E)-2-butenedioate (2:1) (salt)

Networked: 22 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - BRL 26830A: 22
- Alcohols: 595
  - Ethanol: 23169
    - Ethanolamines: 16
      - BRL 26830A: 22
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - BRL 26830A: 22

Experts

1.	Larson, Christopher J: 1 article (01/2019)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/1984 - "BRL 26830A did not affect body weight gain in the lean counterparts of the obese animals because its thermic effect in lean animals was reduced by repeat dosing. " 10/01/1983 - "BRL 26830A did not reduce body weight gain in the lean counterparts of the genetically obese animals. " 01/01/1984 - "It is concluded that BRL 26830A achieves its anti-obesity effect by mimicking natural mechanisms involved in thermogenesis and the control of body weight." 10/01/1983 - "BRL 26830A reduced body weight or weight gain in genetically (ob/ob), goldthioglucose, and cafeteria diet obese mice and genetically obese (fa/fa) Zucker rats. " 01/01/1988 - "Since BRL 26830 restored normoglycaemia in the diabetic mice, without decreasing their body weight, we suppose that it improved insulin action in their muscles and this, in turn, stimulated muscle growth."
2.	Obesity 01/01/1988 - "Forty-three post-menopausal or sterilized female subjects suffering from refractory obesity participated in a double-blind placebo-controlled study, the treatment group receiving BRL 26830A 50 mg qid. " 12/01/1991 - "The beta 3-adrenoceptor agonist, BRL 26830A, which is not inhibited by either beta 1 or beta 2-selective antagonists, has been shown to possess anti-obesity and anti-diabetic actions. " 08/01/1991 - "The anti-obesity and anti-diabetic actions of BRL 26830A, beta 3-adrenoceptor agonist, (2 mg/kg administered intramuscularly daily for 2 weeks) were evaluated in obese diabetic Yellow KK mice and C57B1 control mice. " 08/01/1991 - "Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice." 04/30/1988 - "BRL 26830A may be a useful drug in the treatment of obesity."
3.	Weight Loss (Weight Reduction) 01/01/1992 - "Weight loss was 15.4 +/- 6.6 (SD) kg on BRL 26830A compared with 10.0 +/- 5.9 kg on placebo (P less than 0.02). " 01/01/1991 - "BRL 26830A, which promoted weight loss, did not significantly influence hunger and satiety sensations and was not associated with emotional disturbances during dieting. " 01/01/1991 - "Psychological aspects of dietary weight loss and medication with the atypical beta agonist BRL 26830A in obese subjects." 06/18/1988 - "BRL 26830A and weight loss." 04/30/1988 - "Short term administration of BRL 26830A to six subjects who had taken the drug for 18 weeks showed that the expenditure of energy increased by 11.6% during the second hour after administration, which suggests that BRL 26830A may enhance weight loss thermogenically. "
4.	Insulin Resistance 09/01/1992 - "The results suggest that BRL 26830A improves insulin sensitivity and causes selective down-regulation of adrenergic receptors. " 04/30/1985 - "Effect of a novel thermogenic beta-adrenoceptor agonist (BRL 26830) on insulin resistance in soleus muscle from obese Zucker rats." 05/01/1999 - "Thus, chronic BRL 26830A treatment prevented the development of insulin resistance and attenuated weight gain, but did not prevent the development of obesity in this model." 05/01/1999 - "The aim of this study was to study the effects of chronic BRL 26830A treatment (20 mg/kg/day for 9 weeks) on weight gain and the development of insulin resistance in gold-thioglucose-injected mice (GTG). " 05/01/1999 - "Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice."
5.	Weight Gain 05/01/1999 - "BRL 26830A slowed the rate of weight gain in GTG such that mice weighed significantly less between 2 w and 7 w of treatment. " 10/01/1983 - "BRL 26830A reduced body weight or weight gain in genetically (ob/ob), goldthioglucose, and cafeteria diet obese mice and genetically obese (fa/fa) Zucker rats. " 05/01/1999 - "Thus, chronic BRL 26830A treatment prevented the development of insulin resistance and attenuated weight gain, but did not prevent the development of obesity in this model." 05/01/1999 - "The aim of this study was to study the effects of chronic BRL 26830A treatment (20 mg/kg/day for 9 weeks) on weight gain and the development of insulin resistance in gold-thioglucose-injected mice (GTG). " 05/01/1999 - "Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Adrenergic Receptors (Adrenergic Receptor)
3.	Aurothioglucose (Gold 50)
4.	disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylate
5.	BRL 35135
6.	Glucose (Dextrose)
7.	Anti-Obesity Agents (Antiobesity Drugs)
8.	Glutamic Acid (Glutamate)
9.	Sodium Glutamate (Accent)
10.	Insulin Receptor

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)